top of page
  • ecomber7

What are Pharmaceutical Formulations?

Pharmaceutical formulation refers to the development of drug delivery systems aimed at optimizing drug stability, efficacy, and safety by incorporating active pharmaceutical ingredients (API) and other necessary components. Formulation plays a pivotal role in the drug development pipeline, enhancing treatment effectiveness, reducing dosing frequency, and enabling targeted drug delivery. Long-acting injectables (LAIs) are a specialized type of formulation designed for extended drug release, offering benefits like improved patient compliance and cost-effectiveness. Microsphere formulations, using microencapsulation techniques, are crafted from biodegradable polymers and can be used for LAIs. They provide the advantage of customizable drug release rates. In-situ depot (ISD) LAI formulations, on the other hand, create a reservoir at the injection site to facilitate sustained drug release through methods like polymer precipitation and sol-gel transition. These diverse formulation approaches collectively contribute to the creation of safe and effective drug products, enhancing the well-being of individuals.



Pharmaceutical formulation: 


Pharmaceutical formulation refers to the process of developing a dosage form or drug delivery system that contains the active pharmaceutical ingredient (API) along with other excipients. The aim of formulation is to optimize the delivery of the drug, ensuring its stability, efficacy, and safety. It involves selecting suitable excipients, determining the appropriate dosage form (such as tablets, capsules, injectables, etc.), and designing the formulation to meet specific requirements, such as controlled release, enhanced bioavailability, or targeted delivery.



How do pharmaceutical formulations help people?


Pharmaceutical formulations play a crucial role in drug delivery, ensuring that medications are formulated in a manner that optimizes their effectiveness, safety, and patient compliance. Formulations can enhance the stability and bioavailability of drugs, allowing for sustained release over an extended period. This can improve the efficacy of treatments, reduce the frequency of dosing, and enhance patient convenience and compliance. Additionally, formulations can enable targeted drug delivery, allowing medications to be delivered to specific sites in the body, which can be particularly beneficial for certain diseases or conditions. Overall, pharmaceutical formulations contribute to the development of effective and safe drug products that can positively impact the health and well-being of individuals.




Where does pharmaceutical formulation fit in the drug development pipeline?


Formulations play a crucial role in the drug delivery pipeline. They are involved in the development and optimization of drug delivery systems, which are designed to deliver medications to the intended site of action in the body. Formulations are typically developed after the discovery and characterization of a drug compound. They encompass the selection of suitable excipients, the determination of appropriate dosage forms, and the formulation of drug products that ensure stability, efficacy, and safety. Formulations are an essential component in the translation of drug candidates into viable drug products that are then manufactured, tested, and administered to patients.



Drug Development Timeline
Drug Development Timeline


Types of pharmaceutical formulations:


Pharmaceutical formulations are produced in many forms including:


  • Solid dosage forms: This includes tablets, capsules, and powders, where the active pharmaceutical ingredient (API) is mixed with excipients and compressed into a solid form.

  • Liquid dosage forms: This includes solutions, suspensions, and emulsions, where the API is dissolved or dispersed in a liquid medium.

  • Semi-solid dosage forms: This includes creams, ointments, and gels, where the API is incorporated into a semi-solid base.

  • Parenteral dosage forms: This includes injections, infusions, and implants, where the API is directly administered into the body through intravenous, intramuscular, or subcutaneous routes.

  • Inhalation dosage forms: This includes aerosols, inhalers, and nebulizers, where the API is delivered directly to the respiratory system.



What are long acting injectables (LAIs)?


Long-acting injectables (LAIs) are advanced drug delivery systems designed to release drugs over an extended period, providing a prolonged therapeutic effect. They are a class of drug formulation that can be administered either locally or systemically. LAIs offer several advantages over conventional drug formulations, including improved patient compliance and bioavailability.


The development of LAIs has gained significant attention due to their potential to enhance the long-term bioavailability of drugs and improve treatment efficacy. Prolonged drug exposure can enhance the therapeutic utility of active pharmaceutical ingredients by improving safety and efficacy. LAIs provide sustained release of the drug, reducing the frequency of administration and ensuring a consistent therapeutic effect. This can be particularly beneficial for the treatment of chronic diseases where continuous drug exposure is required. Additionally, LAIs can decrease healthcare costs by reducing visits to healthcare providers and improving patient outcomes.


LAIs can be engineered to provide either local or systemic drug exposure over an extended period. Local LAIs target specific sites of administration, delivering the drug directly to the desired location. Systemic LAIs, on the other hand, release the drug into the bloodstream, circulating around the body to reach its target.


The formulation of LAIs involves complex physico-chemical processes and requires stringent control over their extended release behavior. Designing LAIs necessitates extensive long-term experimental studies to ensure efficacy and reliability. However, recent advancements in information technology, such as machine learning algorithms, have shown promise in predicting experimental drug release from these advanced drug delivery systems. These data-driven approaches have the potential to reduce the time and cost associated with drug formulation development.


The development of LAIs holds great potential in the pharmaceutical industry. They can enable the use of APIs with dose-limiting toxicity or rapid clearance, as well as enhance the safety, convenience, efficacy, or adherence of existing products, extending their lifecycle. However, it is important to note that the specific development and use of LAIs depends on factors such as the pharmacokinetics and pharmacodynamics of the API, the therapeutic area, and the patient population.



Microsphere Formulations 


What are microsphere formulations?


Microsphere formulations are drug delivery systems that consist of small spherical particles made of biocompatible and biodegradable polymers such as polylactide-co-glycolide (PLGA) and polylactic acid (PLA) (see image below). These microspheres can encapsulate proteins, peptides, or other biologically active substances (see image below). They can be suspended in an aqueous vehicle and delivered parenterally using a small gauge needle without anaesthesia. Microspheres have advantages over conventional controlled drug delivery systems, such as the ability to customize the rate and duration of drug release, improved stability compared to other technologies like liposomes, and improved patient compliance due to reduced dose frequency. The release kinetics of microspheres are influenced by factors such as particle size, surface morphology, inner structure, and physicochemical properties of the drug and polymer. 




Microsphere
Microsphere Formulation


How do you make microspheres? 


Some commonly used methods for manufacturing microspheres include:


  • Double emulsion solvent evaporation (most common): This technique involves creating a water-in-oil-in-water emulsion, where the drug or active substance is encapsulated within the internal water phase. The emulsion is then mixed with a polymer solution, and the solvent is evaporated to form solid microspheres.

  • Phase separation-coacervation: In this technique, the polymer and drug are dissolved in a common solvent, and phase separation is induced by changing the conditions such as temperature or pH. This leads to the formation of coacervate droplets, which are then solidified to form microspheres.

  • Spray drying: This method involves atomizing a solution or suspension of the drug and polymer into fine droplets, which are then dried using hot air or a drying gas. The resulting dried particles are collected as microspheres.

  • Gelation and lyophilization: This technique involves converting microspheres into porous microspheres by incubating them in a suitable solution, such as chitosan hydrochloride, and subsequently subjecting them to lyophilization (freeze-drying).

  • Suspension polymerization: In this process, insoluble polymers are solubilized in a monomer solution containing nonpolar active components. The monomer solution is then dispersed in an aqueous phase containing a surfactant or suspending agent. Polymerization is initiated by temperature, irradiation, or a catalyst, resulting in the formation of microspheres.


It is important to note that the specific manufacturing technique used for microsphere production may vary depending on the desired properties, drug characteristics, and intended application.



In-Situ Depot (ISD) Formulations


What are ISD formulations? 


In-situ depot formulations refer to drug delivery systems that are designed to form a depot or reservoir at the site of injection. These formulations are typically administered as a liquid or gel-like solution, which undergoes a phase transition upon injection to form a solid or gel depot within the body. The depot serves as a reservoir for the drug, allowing for sustained release over an extended period of time. In-situ depot formulations are considered promising for long-acting applications due to their ability to provide controlled and prolonged drug release.



In-Situ Depot
In-Situ Depot Formulation


How do you make in-situ depot formulations?


The process of making in-situ depot formulations can involve various approaches. Some common methods include:


  • Polymer precipitation: In this method, a polymer is dissolved in a solvent, and upon injection into the body, the solvent diffuses out, leading to the precipitation of the polymer and the formation of a solid or gel depot.

  • Sol-gel transition: Certain polymers undergo a sol-gel transition when exposed to specific environmental conditions such as temperature, pH, or ion concentration. By incorporating these polymers into the formulation, the liquid solution can transform into a gel or solid depot after injection.

  • Crosslinking: Crosslinking involves chemically or physically linking polymer chains together to form a three-dimensional network. This crosslinked structure can serve as a depot for sustained drug release.


It is important to note that the specific manufacturing processes and techniques may vary depending on the formulation requirements and the type of in-situ depot system being developed.



What are the benefits and limitations of microsphere and ISD formulation?


Strengths and Limitations of Microsphere and In-Situ Depot Formulations
Strengths and Limitations of Microsphere and In-Situ Depot Pharmaceutical Formulations



Recent Posts

See All

Bình luận


bottom of page